Novo Ventures, the corporate venturing unit belonging to pharmaceutical company Novo, has invested in a $33.5m series A round raised by US-based immuno-oncology company Corvus Pharmaceuticals.
The round, raised in December 2014 but disclosed on Wednesday, was led by venture capital firm OrbiMed Advisors and also featured private equity firm Adams Street.
Founded in 2014, Corvus is working on cancer therapies. The company’s lead drug product is a small-molecule checkpoint inhibitor, a type of treatment that enables the body’s immune…
